Search results
Results from the WOW.Com Content Network
Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows Lindsey Leake Updated December 20, 2024 at 6:48 PM
(Reuters) -AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low ...
AstraZeneca said Imfinzi was also recently granted Breakthrough Therapy Designation by the FDA in the same setting, which will help accelerate the regulatory review. Small cell lung cancer is a ...
In 2019 AstraZeneca agreed to pay up to US$6.9 billion to jointly develop DS-8201 with Japan's Daiichi Sankyo. It is intended to replace Herceptin for treating breast cancer. DS8201 carries eight payloads, compared to the usual four. [2]
Durvalumab, [8] sold under the brand name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. [9] It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 with the PD-1 (CD279).
Endocrine-Related Cancer was founded as Reviews on Endocrine-Related Cancer, the in-house journal of Zeneca (now AstraZeneca) published by its parent company ICI Pharmaceuticals. It was taken over by the Society for Endocrinology in 1994 when it was renamed, and the remit was extended to include a limited number of original research articles to ...
Monday, AstraZeneca Plc (NASDAQ:AZN) shared detailed results from the TROPION-Lung01 Phase 3 of datopotamab deruxtecan (Dato-DXd) compared to docetaxel, the current standard of care chemotherapy ...
Vandetanib, sold under the brand name Caprelsa, is an anti-cancer medication that is used for the treatment of certain tumours of the thyroid gland.It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor, the epidermal growth factor receptor, and the RET-tyrosine kinase.